Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 1, 2011, Pages 9-19

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

amlodipine; antihypertensive agents; cardiovascular diseases; hypertension; multimodal; olmesartan; treatment

Indexed keywords

ALCOHOL; AMINE; AMLODIPINE BESYLATE; AMLODIPINE BESYLATE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN MEDOXOMIL; AMLODIPINE PLUS OLMESARTAN; ANION EXCHANGE RESIN; ANTIDIABETIC AGENT; BARBITURIC ACID DERIVATIVE; CORTICOSTEROID; CORTICOTROPIN; CYTOCHROME P450 3A4; DIGOXIN; HYDROCHLOROTHIAZIDE; LITHIUM; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; REVIEW; RISK FACTOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 78650399272     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.163     Document Type: Review

References (38)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 303, 2043-2050 (2010).
2. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
3. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 4, 393-404 (2002).
4. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005).
5. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009).
6. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
7. Elijovich FD, Laffer CD. A role for single-pill triple therapy in hypertension. Ther. Adv. Cardiovasc. Dis. 3, 231-240 (2009).
8. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202, 1028-1034 (1967).
9. Tribenzor (package insert). Daiichi Sankyo Inc. NJ USA( 2010).
10. Chrysant SG, Weber MA, Wang AC et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17, 252-259 (2004).
11. Chrysant SG, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial effcacy and safety study. Clin. Ther. 30, 587-604 (2008).
12. Lacy CF, Armstrong LL, Goldman MP et al. Drug Information Handbook (14th Edition). Lexi-Comp, OH, USA (2006).
13. Physician's Desk Reference (62nd Edition). Thomson PDR, NJ, USA (2008).
14. Laeis P, Puchler K, Kirch W The pharmacokinetic and metabolic profle of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. Suppl. 19, S21-S32 (2001).
15. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol. 41, 515-527 (2001).
16. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol. 285, 181-188 (1995).
17. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan- amlodipine combination. Vasc. Health Risk Manag. 4, 653-664 (2008).
18. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin. Pharmacokinet. 22, 22-31 (1992).
19. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41, 478-505 (1991).
20. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their inter changeability Hypertension 43, 4-9 (2004).
21. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc. Health Risk Manag. 2, 401-409 (2006).
22. Oparil S, Melino M, Lee J et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINTY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32, 1252-1269 (2010).
23. Chrysant SG, Oparil S, Melino M et al. Effcacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens. (Greenwich) 11, 475-482 (2009).
24. Volpe M, Miele C, Haag U. Effcacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with mo derate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29, 381-391 (2009).
25. Kereiakes DJ, Sachson RA, Qian C et al Effcacy and onset of antihypertensive effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and Type 2 diabetes [PO-233]. J. Clin. Hypertens. 12(Suppl. 1), A111-A112 (2010).
26. Weir MR, Weber MA, Nesbitt SD et al. Rationale and design of the BP CRUSH study: evaluation the effcacy and safety of amlodipine/olmesartan medoxomil in patients who are non-responders to antihypertensive monotherapy (abstract P-297). J. Clin. Hypertens. 11, A136-A137 (2009).
27. Ram VS, Sachson RA, Qian C et al. Effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension, Type 2 diabetes and metabolic syndrome (abstract PO- 193). J. Clin. Hypertens. 21(Suppl. 1), A96 (2010).
28. Chrysant SG, Neutel JM, Qian C et al The safety and tolerability profle of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and Type 2 diabetes (abstract PO-204). J. Clin. Hypertens. 12(Suppl. 1), A100-A101 (2010).
29. Gradman AH, Basile JN, Carter BL et al Combination therapy in hypertension. J. Am. Soc. Hypertens. 4, 42-50 (2010).
30. Wald DS, Law M, Morris JK et al Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-300 (2009).
31. Staessen JA, Thijisq L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 22, 847-857 (2004).
32. Weber MA, Julius S, Kjeldsen SE et al Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363, 2049-2051 (2004).
33. Nasser SA, Lai Z, O'Connor S et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events Curr. Hypertens. Rep. 10, 398-404 (2008).
34. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fxed-dose combination therapy. Ther. Adv. Cardiovasc. Dis. 4, 119-127 (2010).
35. Dusing R. Optimizing blood pressure control through the use of fxed combinations. Vasc. Health Risk Manag. 6, 321-325 (2010).
36. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fxed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55, 399-407 (2010).
37. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120, 713-719 (2007).
38. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).